Improving the Efficacy of Cisplatin using Niosome Nanoparticles Against Human Breast Cancer Cell Line BT-20 : An In Vitro Study

Authors

  • Leila Kanaani
  • Maral Mazloumi Tabrizi Department of Toxicology and Pharmacology, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran.
  • Azim Akbarzadeh Khiyavi Department of Pilot Nanobiotechnology, Pasteur Institute of Iran, Tehran, Iran.
  • Iraj Javadi Department of Toxicology, Faculty of Pharmacy, Islamic Azad University, Shahreza Branch Isfahan, Iran.

Keywords:

Nanoniosome- cisplatin- breast cancer

Abstract

Objective: Today, cancer is one the most important challenges in modern medicine. Meanwhile, breast cancer is one of the most common causes of mortality among cancers. The initial response to the treatment and then becoming resistant to the cisplatin is one of basal challenges of treatment of breast cancer. Recently, using nanotechnology including drug nanocarrier named niosome can decrease adverse effects and increase the efficiency of treatment.
Material and Methods: The aim of this research was to investigate using niosome nanoparticles containing cisplatin and investigation of their lethal effect on breast cancer cell line.
Results: We found that using niosome nanoparticles can provide a suitable formulation of cisplatin drug.
Conclusion: The efficiency of nanoniosome cisplatin was more than free drug, decreasing the administered dose and therefore the damage to other tissues.

Downloads

Published

2017-06-25

Issue

Vol. 2 No. 2 (2017)

Section

Research Articles/ Original Work

License

 West Asia Organization for Cabcer Prevention retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License 4 (This permits anyone to copy, distribute, transmit and adapt the published work, provided the original work and source are appropriately cited).